Literature DB >> 15194568

Time dependent risk of gastrointestinal complications induced by non-steroidal anti-inflammatory drug use: a consensus statement using a meta-analytic approach.

F Richy1, O Bruyere, O Ethgen, V Rabenda, G Bouvenot, M Audran, G Herrero-Beaumont, A Moore, R Eliakim, M Haim, J-Y Reginster.   

Abstract

OBJECTIVES: To provide an updated document assessing the global, NSAID-specific, and time dependent risk of gastrointestinal (GI) complications through meta-analyses of high quality studies.
METHODS: An exhaustive systematic search was performed. Inclusion criteria were: RCT or controlled study, duration of 5 days at least, inactive control, assessment of minor or major NSAID adverse effects, publication range January 1985 to January 2003. The publications retrieved were assessed during a specifically dedicated WHO meeting including leading experts in all related fields. Statistics were performed conservatively. Meta-regression was performed by regressing NSAID adjusted estimates against study duration categories.
RESULTS: Among RCT data, indolic derivates provided a significantly higher risk of GI complications related to NSAID use than for non-users: RR = 2.25 (1.00; 5.08) than did other compounds: naproxen: RR = 1.83 (1.25; 2.68); diclofenac: RR = 1.73 (1.21; 2.46); piroxicam: RR = 1.66 (1.14; 2.44); tenoxicam: RR = 1.43 (0.40; 5.14); meloxicam: RR = 1.24 (0.98; 1.56), and ibuprofen: RR = 1.19 (0.93; 1.54). Indometacin users had a maximum relative risk for complication at 14 days. The other compounds presented a better profile, with a maximum risk at 50 days. Significant additional risk factors included age, dose, and underlying disease. The controlled cohort studies provided higher estimates: RR = 2.22 (1.7; 2.9). Publication bias testing was significant, towards a selective publication of deleterious effects of NSAIDs from small sized studies.
CONCLUSION: This meta-analysis characterised the "compound" and "time" aspects of the GI toxicity of non-selective NSAIDs. The risk/benefit ratio of such compounds should thus be carefully and individually evaluated at the start of long term treatment.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15194568      PMCID: PMC1755051          DOI: 10.1136/ard.2003.015925

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  75 in total

1.  Role of Helicobacter pylori infection and non-steroidal anti-inflammatory drugs in peptic-ulcer disease: a meta-analysis.

Authors:  Jia Qing Huang; Subbaramiah Sridhar; Richard H Hunt
Journal:  Lancet       Date:  2002-01-05       Impact factor: 79.321

2.  A cohort study (with re-sampled comparator groups) to measure the association between new NSAID prescribing and upper gastrointestinal hemorrhage and perforation.

Authors:  A D McMahon; J M Evans; G White; F E Murray; M M McGilchrist; D G McDevitt; T M MacDonald
Journal:  J Clin Epidemiol       Date:  1997-03       Impact factor: 6.437

3.  Flurbiprofen inhibits heterotopic bone formation in total hip arthroplasty.

Authors:  V Hoikka; T S Lindholm; A Eskola
Journal:  Arch Orthop Trauma Surg       Date:  1990       Impact factor: 3.067

Review 4.  Identifying relevant studies for systematic reviews.

Authors:  K Dickersin; R Scherer; C Lefebvre
Journal:  BMJ       Date:  1994-11-12

5.  Indomethacin for prevention of heterotopic ossification. A randomized controlled study in 41 hip arthroplasties.

Authors:  P Kjaersgaard-Andersen; A Nafei; G Teichert; O Kristensen; S A Schmidt; J Keller; U Lucht
Journal:  Acta Orthop Scand       Date:  1993-12

6.  Gastrointestinal tolerability of meloxicam and piroxicam: a double-blind placebo-controlled study.

Authors:  G R Lipscomb; N Wallis; G Armstrong; W D Rees
Journal:  Br J Clin Pharmacol       Date:  1998-08       Impact factor: 4.335

7.  Oral diclofenac in the prophylactic treatment of recurrent renal colic. A double-blind comparison with placebo.

Authors:  E Laerum; O E Ommundsen; J E Grønseth; A Christiansen; H E Fagertun
Journal:  Eur Urol       Date:  1995       Impact factor: 20.096

8.  Nonsteroidal anti-inflammatory drugs and hospitalization for gastroesophageal bleeding in the elderly.

Authors:  K Beard; A M Walker; D R Perera; H Jick
Journal:  Arch Intern Med       Date:  1987-09

9.  Double-blind, placebo-controlled comparison of the safety and efficacy of orally administered etodolac and nabumetone in patients with active osteoarthritis of the knee.

Authors:  T J Schnitzer; I M Ballard; G Constantine; P McDonald
Journal:  Clin Ther       Date:  1995 Jul-Aug       Impact factor: 3.393

10.  Gastrointestinal damage associated with the use of nonsteroidal antiinflammatory drugs.

Authors:  M C Allison; A G Howatson; C J Torrance; F D Lee; R I Russell
Journal:  N Engl J Med       Date:  1992-09-10       Impact factor: 91.245

View more
  39 in total

1.  Nonsteroidal anti-inflammatory drug use in ankylosing spondylitis--a population-based survey.

Authors:  Jane Zochling; Martin H J Bohl-Bühler; Xenofon Baraliakos; Ernst Feldtkeller; Jürgen Braun
Journal:  Clin Rheumatol       Date:  2006-03-10       Impact factor: 2.980

2.  Analysis and quantification of self-medication patterns of customers in community pharmacies in southern Chile.

Authors:  Katherine Fuentes Albarrán; Lorenzo Villa Zapata
Journal:  Pharm World Sci       Date:  2008-08-20

3.  NSAID, antiaggregant, and/or anticoagulant-related upper gastrointestinal bleeding: Is there any change in prophylaxis rate after a 10-year period?

Authors:  Dinç Dinçer; Ece Ulukal Karancı; Mete Akın; Haydar Adanır
Journal:  Turk J Gastroenterol       Date:  2019-06       Impact factor: 1.852

4.  Outcomes From a Pharmacist - led Proton Pump Inhibitor Stewardship Program at a Single Institution.

Authors:  Rebekah A Wahking; Randal L Steele; Rachel E Hanners; Sean M Lockwood; Kelly W Davis
Journal:  Hosp Pharm       Date:  2017-12-13

Review 5.  Management of co-morbidities and general medical conditions in patients with rheumatoid arthritis.

Authors:  Molly D Magnano; Mark C Genovese
Journal:  Curr Rheumatol Rep       Date:  2005-10       Impact factor: 4.592

6.  Comparison of nonsteroidal anti-inflammatory drugs and cyclooxygenase-2 (COX-2) inhibitors use in Australia and Nova Scotia (Canada).

Authors:  Nadia Barozzi; Ingrid Sketris; Charmaine Cooke; Susan Tett
Journal:  Br J Clin Pharmacol       Date:  2009-07       Impact factor: 4.335

7.  Changing prevalence of Helicobacter pylori infection and peptic ulcer among dyspeptic Sardinian patients.

Authors:  Maria Pina Dore; Giuseppina Marras; Chiara Rocchi; Sara Soro; Maria Francesca Loria; Gabrio Bassotti; David Y Graham; Hoda M Malaty; Giovanni M Pes
Journal:  Intern Emerg Med       Date:  2015-03-05       Impact factor: 3.397

Review 8.  Should nonsteroidal anti-inflammatory drugs (NSAIDs) be prescribed to the older adult?

Authors:  Robert L Barkin; Mihail Beckerman; Steven L Blum; Frank M Clark; Eun-Kyu Koh; Dickson S Wu
Journal:  Drugs Aging       Date:  2010-10-01       Impact factor: 3.923

9.  Preemptive Genotyping of CYP2C8 and CYP2C9 Allelic Variants Involved in NSAIDs Metabolism for Sickle Cell Disease Pain Management.

Authors:  Cheedy Jaja; Latanya Bowman; Leigh Wells; Niren Patel; Hongyan Xu; Matt Lyon; Abdullah Kutlar
Journal:  Clin Transl Sci       Date:  2015-02-02       Impact factor: 4.689

10.  NSAIDs and the gastrointestinal tract.

Authors:  Maneesh Gupta; Glenn M Eisen
Journal:  Curr Gastroenterol Rep       Date:  2009-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.